Introduction
Elderly patients are more likely than younger patients to present with locally advanced basal cell carcinoma (BCC), which can be challenging to treat with standard therapies. 1 Conventional treatment methods may need to be adapted for this patient population because of their vulnerability to toxicity, social barriers to care, and patient preferences. This case illustrates the use of stereotactic ablative radiotherapy (SABR) as a curative treatment of patients with locally advanced BCC who are not surgical candidates.
Case Report
An 81-year-old woman presented with a large biopsy-confirmed BCC on her nose (Fig 1A) that had been growing over a period of 8 years. The lesion was not causing any pain, bleeding, or nasal obstruction. On examination, she had a wellcircumscribed exophytic lesion on the surface of her nose, measuring 4 cm 3 4 cm 3 3 cm, with no evidence of nasal mucosal invasion. Computed tomography imaging showed no erosion of bone, septal invasion, or lymphadenopathy. This was a T2N0, stage II BCC (American Joint Committee on Cancer 8th edition). She had no known comorbidities, was not taking any medications, and was living independently. Surgical resection was not recommended because of the need for a near total rhinectomy. Vismodegib was not recommended because of the adverse effect profile, long duration of treatment, and lower likelihood of complete response. Radiation therapy was recommended; however, the patient declined standard-dose fractionation (66 Gy in 30 fractions) because of her concerns about tolerating the 6 weeks of daily therapy. She was therefore treated with curative intent using SABR to a dose of 40 Gy in five fractions, once per week. During treatment, she experienced intermittent pain and nasal congestion and required regular dressing changes for her wound. The lesion was not visible 3 months post treatment, and there is no evidence of recurrence at 26 months (Fig 1B) . She has occasional ongoing congestion, and on examination there is mild fibrosis, atrophy, and telangiectasias in the area of treatment.
Discussion
Elderly patients are more likely to present with advanced BCCs for several reasons, including social isolation, cognitive impairment, and comorbidities. Surgery is the mainstay of treatment; however, radiation can be considered for patients who do not undergo surgery. Standard radiation regimens include 60 to 70 Gy over 6 to 7 weeks, or 45 to 55 Gy over 3 to 4 weeks, which can be difficult to tolerate because of repeated hospital visits. Vismodegib, an oral inhibitor of Smoothened, can be another option if surgery and radiation are not possible; however, adverse effects, such as muscle spasms, dysgeusia, alopecia, GI upset, weight loss, and fatigue, can be challenging, particularly for older patients.
1 Grade 3 to 5 adverse events have been shown to occur in 25% to 51% of patients $ 65 years old. 1 Shorter, hypofractionated radiation regimens, using between three and 20 fractions, have demonstrated high efficacy for the treatment of BCC, and local control rates are reported to be . 90% (Table 1) . [2] [3] [4] [5] Despite excellent results, the use of shorter regimens has historically been limited to selected cases because of the inability to conform and shape radiotherapy to the tumor, resulting in risk of excessive toxicity. SABR is a technique of delivering highly precise, high-dose radiotherapy in a short number of treatments, usually between one and five. Immobilization and image guidance are used to improve accuracy and decrease radiation dose to the surrounding normal tissue.
In conclusion, SABR can provide an efficient, convenient, and effective treatment option for patients who do not undergo standard treatment of locally advanced BCC and should be considered particularly for elderly patients. Multidisciplinary care that includes consideration of alternative radiation treatment schedules is invaluable in addressing the unique needs of this population.
